Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Data shows that 99% of Polymarket traders cannot consistently make stable profits

Data shows that 99% of Polymarket traders cannot consistently make stable profits

Odaily星球日报Odaily星球日报2026/04/09 06:06
Show original

According to Odaily, crypto analyst Andrey Sergeenkov released data on Monday showing that only 0.015% of Polymarket traders were able to consistently earn over $5,000 in monthly income for four consecutive months. The data reveals that nearly 1% of traders made a profit exceeding $5,000 in a single month, but just 0.1% managed to repeat this performance in the following month. Out of approximately 2.5 million wallets, only 840 wallets achieved cumulative profits of more than $100,000, and these included trading accounts of professional institutions such as hedge funds.

Among the more profitable traders, most did not remain on the platform for the long term. Of the 6,600 wallet addresses with average monthly profits over $5,000, only 172 stayed active for more than a year, accounting for just 2.6%. Sergeenkov stated that most traders leave after short-term trading. This analysis only includes realized profits and losses, and the data covers the period from April 2024 to April 1, 2026.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Goldman Sachs comments on AMD (AMD.US) Q3 performance: Data center CPU and GPU show strong performance, growth visibility for 2027 is clear

Goldman Sachs released a research report maintaining a "Buy" rating on AMD (AMD.US) with a 12-month target price of $675.

智通财经•2026/11/04 03:53

AbbVie (ABBV.US) expands Oxford R&D facility in UK, betting on innovation in immunology, neuroscience, and oncology drugs

AbbVie announced on Wednesday that, as part of an investment plan exceeding 120 million pounds (approximately $161 million), the company has expanded its research and development facility in Oxford, United Kingdom.

智通财经•2026/11/04 02:51